At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KYMR Kymera Therapeutics, Inc.
Pre-Mkt 12-23 05:59:51 EST
84.35
+0.36
+0.43%
盘前84.40
+0.05+0.06%
05:09 EST
High85.41Low82.87Vol804.42K
Open84.73D1 Closing83.99Amplitude3.02%
Mkt Cap6.66BTradable Cap4.61BTotal Shares78.95M
T/O67.98MT/O Rate1.47%Tradable Shares54.63M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Did KT-621 Fast Track Status Just Shift Kymera Therapeutics' (KYMR) Investment Narrative?
Simply Wall St.  ·  12-22 22:13
Did KT-621 Fast Track Status Just Shift Kymera Therapeutics' (KYMR) Investment Narrative?
Kymera Therapeutics Inc : B. Riley Raises Target Price to $117 From $80
THOMSON REUTERS  ·  12-22 21:27
Kymera Therapeutics Inc : B. Riley Raises Target Price to $117 From $80
B. Riley Raises Price Target on Kymera Therapeutics to $117 From $80, Keeps Buy Rating
MT Newswires Live  ·  12-22 21:00
B. Riley Raises Price Target on Kymera Therapeutics to $117 From $80, Keeps Buy Rating
Kymera Therapeutics (KYMR): Valuation Check After KT-621 Phase 1b Success and FDA Fast Track Nod
Simply Wall St.  ·  12-21 01:14
Kymera Therapeutics (KYMR): Valuation Check After KT-621 Phase 1b Success and FDA Fast Track Nod
BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks
Reuters  ·  12-17
BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks
BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse
Reuters  ·  12-17
BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse
BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026
Reuters  ·  12-17
BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026
Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says
MT Newswires Live  ·  12-17
Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says
Kymera Therapeutics Is Maintained at Outperform by RBC Capital
Dow Jones  ·  12-16
Kymera Therapeutics Is Maintained at Outperform by RBC Capital
RBC Raises Price Target on Kymera Therapeutics to $103 From $70, Keeps Outperform, Speculative Risk
MT Newswires Live  ·  12-16
RBC Raises Price Target on Kymera Therapeutics to $103 From $70, Keeps Outperform, Speculative Risk
Director Bruce Booth Reports Disposal of Kymera Therapeutics Inc. Common Shares
Reuters  ·  12-13
Director Bruce Booth Reports Disposal of Kymera Therapeutics Inc. Common Shares
S&P 500 Futures Drop In Premarket Trading; Fermi, Broadcom Lag
Dow Jones  ·  12-12
S&P 500 Futures Drop In Premarket Trading; Fermi, Broadcom Lag
Baker Bros. Advisors LP Reports Acquisition of Kymera Therapeutics Inc. Common Shares
Reuters  ·  12-12
Baker Bros. Advisors LP Reports Acquisition of Kymera Therapeutics Inc. Common Shares
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire  ·  12-12
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
FDA Grants Fast Track Designation to Kymera Therapeutics’ KT-621 for Atopic Dermatitis
Reuters  ·  12-11
FDA Grants Fast Track Designation to Kymera Therapeutics’ KT-621 for Atopic Dermatitis
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral Stat6 Degrader for the Treatment of Atopic Dermatitis
THOMSON REUTERS  ·  12-11
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral Stat6 Degrader for the Treatment of Atopic Dermatitis
Kymera Therapeutics Inc - KT-621 Phase 2B Ad Trial Data Expected by Mid-2027
THOMSON REUTERS  ·  12-11
Kymera Therapeutics Inc - KT-621 Phase 2B Ad Trial Data Expected by Mid-2027
Kymera Therapeutics Inc : Mizuho Raises Target Price to $120 From $81
THOMSON REUTERS  ·  12-11
Kymera Therapeutics Inc : Mizuho Raises Target Price to $120 From $81
Kymera Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones  ·  12-11
Kymera Therapeutics Is Maintained at Overweight by JP Morgan
BRIEF-Kymera Therapeutics Announces Pricing Of Upsized $602 Million Public Offering At $86 Per Share
Reuters  ·  12-10
BRIEF-Kymera Therapeutics Announces Pricing Of Upsized $602 Million Public Offering At $86 Per Share

Introduction

Company Name.
Kymera Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Issue price:
--